The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) plus radiotherapy in the treatment of lung adenocarcinoma patients with central nervous system metastases: a meta-analysiss
10.3760/cma.j.cn431274-20200430-00541
- VernacularTitle:EGFR-TKI联合放疗治疗肺腺癌伴有中枢神经系统转移的meta分析
- Author:
Yue ZHAO
1
;
Xinyi XU
;
Qinyuan LU
;
Xilong ZHANG
;
Hanpeng HUANG
Author Information
1. 江苏大学附属医院呼吸内科，镇江 212003
- Keywords:
Adenocarcinoma, lung;
Central nervous system neoplasms;
Neoplasm metastasis;
Epidermal growth factor receptor-tyrosine kinase inhibitor;
Antineoplastic co
- From:
Journal of Chinese Physician
2021;23(7):1017-1021
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combined with radiotherapy in the treatment of lung adenocarcinoma with central nervous system (CNS) metastasis.Methods:PubMed, EMBASE, Medline, Cochrane Library, clinical trials and other databases were searched to collect the clinical control studies of EGFR-TKI combined with radiotherapy versus EGFR-TKI or radiotherapy alone in the treatment of lung adenocarcinoma with CNS metastasis published at home and abroad from January 2012 to April 2019. After evaluating the data, Revman 5.3 software was used for meta-analysis.Results:10 studies involving 1 379 participants were included. The results indicated that compared with EGFR-TKI or radiotherapy alone, EGFR-TKI plus radiotherapy had a significant benefit on overall response rate (ORR) [ OR: 3.81, 95% CI(1.73, 8.39); P<0.01], overall survival (OS) [ HR: 0.60, 95% CI(0.41, 0.89); P=0.01], neurological progression free survival (nPFS) [ HR: 0.65, 95% CI(0.46, 0.91); P=0.01] compared with EGFR-TKI or radiotherapy alone. Conclusions:EGFR-TKI plus radiotherapy had better ORR, OS, nPFS compared with TKI or radiotherapy alone.
